Simvastatin
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Simvastatin: From Hyperlipidaemia and Atherosclerosis to Familial Hypercholesterolemia
One-Sentence Summary
Simvastatin is a statin originally used to treat hyperlipidaemia, atherosclerosis, stroke-related disorders and homozygous familial hypercholesterolemia. The TxGNN model predicts it may be effective for familial hypercholesterolemia, supported by 8 clinical trials and 20 publications in the data compiled for this report. This indication largely overlaps with simvastatin's existing lipid-lowering uses, so it is better viewed as confirmation of an established use than as a new repurposing opportunity.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertriglyceridemia, atherosclerosis, stroke and cerebrovascular disorders, homozygous familial hypercholesterolemia and related lipid disorders (from the knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Familial hypercholesterolemia |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L1 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, simvastatin is an HMG-CoA reductase inhibitor. It lowers cholesterol synthesis in the liver and increases LDL receptors, which speeds up clearance of LDL cholesterol from the blood.
Familial hypercholesterolemia is an inherited condition with a defect in LDL clearance. In heterozygous patients, statins work by increasing LDL receptor expression from the remaining functional gene copy. The original indications already include homozygous familial hypercholesterolemia and hyperlipoproteinemia. The prediction therefore sits very close to the established use.
The same pattern appears for the fourth-ranked prediction, autosomal dominant hypercholesterolemia, which is also supported by Phase 3 trials and guidelines but overlaps with existing indications.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00552097 | Phase 3 | Completed | 720 | ENHANCE: ezetimibe plus high-dose simvastatin vs simvastatin alone on carotid atherosclerosis progression in heterozygous FH |
| NCT00129402 | Phase 3 | Completed | 248 | Ezetimibe with simvastatin vs simvastatin alone in adolescents (10-17 years) with heterozygous FH |
| NCT03884452 | Phase 3 | Completed | 50 | Ezetimibe added to atorvastatin or simvastatin in homozygous FH |
| NCT03885921 | Phase 3 | Completed | 44 | 24-month open-label safety extension of ezetimibe plus atorvastatin or simvastatin in homozygous FH |
| NCT01709500 | Phase 3 | Completed | 249 | Alirocumab vs placebo in heterozygous FH on lipid-modifying therapy (simvastatin's role unconfirmed) |
| NCT00654446 | Phase 3 | Completed | 442 | Renal effects of rosuvastatin vs simvastatin in type IIa/IIb dyslipidaemia, including heterozygous FH |
| NCT03510884 | Phase 3 | Completed | 153 | Alirocumab in children and adolescents with heterozygous FH on statin therapy (indirect evidence) |
| NCT01890967 | Phase 2 | Completed | 527 | LY3015014 dose-ranging in primary hypercholesterolemia with background statins (indirect evidence) |
| NCT03510715 | Phase 3 | Completed | 18 | Open-label alirocumab in children and adolescents with homozygous FH (indirect evidence) |
The trials most directly relevant to simvastatin are NCT00552097 and NCT00129402. Several of the others test other drugs, with simvastatin at most as background therapy.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18376000 | 2008 | Trial report (ENHANCE) | N Engl J Med | Simvastatin with or without ezetimibe in familial hypercholesterolemia |
| 41824590 | 2026 | Guideline | J Am Coll Cardiol | 2026 ACC/AHA dyslipidaemia guideline, replacing the 2018 cholesterol guideline |
| 41824552 | 2026 | Guideline | Circulation | Same 2026 dyslipidaemia guideline (parallel publication) |
| 28437620 | 2017 | Guideline | Endocr Pract | AACE/ACE guidelines for dyslipidaemia management and cardiovascular prevention |
| 31696945 | 2019 | Cochrane review | Cochrane Database Syst Rev | Statins for children with familial hypercholesterolemia |
| 12908847 | 2003 | Review | Drug Saf | Benefits and risks of simvastatin in familial hypercholesterolaemia |
| 15794711 | 2005 | Review | Expert Opin Drug Saf | Benefit-risk assessment of simvastatin in familial hypercholesterolaemia |
| 35361995 | 2022 | Genetic/cohort | Pharmacogenomics J | Combined FH and statin pharmacogenomic testing strategy |
| 35629051 | 2022 | Cross-sectional | J Clin Med | Cellular immunity in children with FH treated with 10 mg simvastatin |
| 1346327 | 1992 | Clinical study | Lancet | Simvastatin and lipoprotein(a) |
Singapore Market Information
All 20 registrations are single-ingredient, film-coated oral tablets and are currently valid. No approved indication text is recorded in the licence data. The main authorizations are listed below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN03789P | ZOCOR TABLET 10 mg | Film-coated tablet | Not recorded |
| SIN08893P | ZOCOR TABLET 20 mg | Film-coated tablet | Not recorded |
| SIN13482P | Apo-Simvastatin 10mg Tablet | Film-coated tablet | Not recorded |
| SIN14454P | KARDAK 40 FILM-COATED TABLETS 40 MG | Film-coated tablet | Not recorded |
| SIN12094P | COVASTIN TABLET 40 mg | Film-coated tablet | Not recorded |
Safety Considerations
Contraindications suggested by the knowledge graph (these are model-derived associations, not label text): liver disease, pancreatitis, myopathy and other muscle diseases, rhabdomyolysis, gallbladder disease, diabetes and hyperglycaemia, gout, thrombocytopenia, blood coagulation disease, and acute coronary syndrome/myocardial infarction, among others.
Drug Interactions (100 interactions were found; main ones shown):
- Major: amiodarone, amlodipine, fenofibrate
- Moderate: nifedipine, paclitaxel, omeprazole, zidovudine, aprepitant, ethanol, among others
Simvastatin is metabolised by CYP3A4, so potent CYP3A4 inhibitors raise exposure and the risk of myopathy. Boosted HIV protease inhibitors and cobicistat are of particular concern, and a biopsy-proven myopathy case with Genvoya plus simvastatin has been reported.
Please refer to the package insert for official warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Several completed Phase 3 trials, Cochrane reviews and current guidelines support simvastatin in familial hypercholesterolemia, which is consistent with its established lipid-lowering use. This is not a true repurposing opportunity, so the practical question is about indication scope and safe use.
To proceed, the following is needed:
- HSA package insert warnings and contraindications, which are currently missing and block the safety screening
- Approved indication text for the Singapore licences, to confirm whether heterozygous familial hypercholesterolemia is already covered
- Detailed mechanism of action data from DrugBank
- A guardrail for CYP3A4 interactions, dose limits with amiodarone and amlodipine, and myopathy and liver monitoring
Other predictions:
- Autosomal dominant hypercholesterolemia has the same L1 evidence and decision (Proceed with Guardrails), with the same overlap with existing indications.
- HIV infectious disease is a research question only (L3). The trials are drug-interaction studies, not efficacy studies, and safety is the main concern.
- All other predictions (brain stem infarction, CETP deficiency, CYP7A1 deficiency, ABri amyloidosis, a rare neurodevelopmental disorder, fibroma of prostate, feline AIDS) rest on model prediction alone (L5) and should be on Hold.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.